Inwha Cho, MD
Neurology · Baltimore, MDNPI 1861451767
Payments from drug & device makers
Across 361 payments — averaging $22.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Novartis$784
- Lilly USA, LLC$525
- EMD Serono, Inc.$473
- Biogen$461
- SK Life Science, Inc.$449
- plus $4K from 27 others
What the payments were for
- Food & beverage$8,06699%
- Education$1111%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 70 | $1,279 |
| Novartis | 57 | $784 |
| Lilly USA, LLC | 26 | $525 |
| EMD Serono, Inc. | 14 | $473 |
| Biogen | 17 | $461 |
| SK Life Science, Inc. | 9 | $449 |
| UCB, Inc. | 15 | $424 |
| AstraZeneca | 9 | $397 |
| Teva Pharmaceuticals USA, Inc. | 10 | $385 |
| Amgen(2 entities) | 17 | $348 |
| Eisai Inc. | 12 | $284 |
| Lundbeck LLC | 10 | $263 |
| Pfizer | 12 | $250 |
| Neurelis, Inc. | 12 | $237 |
| Sumitomo Pharma America, Inc. | 11 | $207 |
| Genentech USA, Inc. | 8 | $195 |
| Neurocrine Biosciences, Inc. | 8 | $180 |
| Supernus Pharmaceuticals, Inc. | 10 | $131 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $125 |
| Sunovion Pharmaceuticals Inc. | 2 | $111 |
| Sanofi | 6 | $91 |
| Averitas Pharma Inc. | 3 | $84 |
| Grifols USA, LLC | 3 | $83 |
| Jazz Pharmaceuticals Inc. | 3 | $81 |
| CSL Behring | 3 | $73 |
| Johnson & Johnson | 2 | $50 |
| Biohaven Pharmaceuticals, Inc. | 1 | $50 |
| Revance Therapeutics, Inc. | 1 | $38 |
| Aucta Pharmaceuticals, Inc. | 2 | $36 |
| TG Therapeutics, Inc. | 1 | $24 |
| Kedrion Biopharma, Inc. | 1 | $22 |
| Livanova USA, Inc. | 1 | $20 |
| Avion Pharmaceuticals | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,178 in reported general payments places this provider in the 60th percentile of 442 neurology providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Avonex (4 Pack)Interferon Beta-1a | 13 | $105,307 |
| CopaxoneGlatiramer Acetate | 13 | $76,423 |
| UbrelvyUbrogepant | 22 | $35,918 |
| Nurtec OdtRimegepant Sulfate | 12 | $23,894 |
| QuliptaAtogepant | 17 | $21,888 |
| AptiomEslicarbazepine Acetate | 12 | $15,367 |
| Emgality PenGalcanezumab-Gnlm | 12 | $12,079 |
| Levetiracetam | 134 | $3,754 |
| Lacosamide | 35 | $3,542 |
| Dimethyl Fumarate | 12 | $2,460 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 65 | $1,797 |
| Memantine Hcl | 69 | $1,753 |
| Donepezil Hcl | 153 | $1,147 |
| Carbamazepine | 17 | $839 |
| Topiramate | 67 | $765 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| BiogenAvonex (4 Pack) | $461 | $105,30713 claims |
| Teva Pharmaceuticals USA, Inc.Copaxone | $385 | $76,42313 claims |
| AbbVieUbrelvy, Qulipta | $1,279 | $57,80639 claims |
| PfizerNurtec Odt | $250 | $23,89412 claims |
| Sunovion Pharmaceuticals Inc.Aptiom | $111 | $15,36712 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 442 neurology providers in Maryland.
Other neurology in Baltimore
- Ellen MowryBaltimore$5.7M
- Michael PolydefkisBaltimore$4.1M
- Jeffrey RothsteinBaltimore$3M
- Pavan BhargavaBaltimore$2.8M
- Thomas CrawfordBaltimore$2.4M
- Nicholas MaragakisBaltimore$2.2M
- Shiv SaidhaBaltimore$2.1M
- Karisa SchreckBaltimore$1.9M
- Scott NewsomeBaltimore$1.7M
- Kathryn WagnerBaltimore$1.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.